CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
Hyerim Ha, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Cancer Research and Treatment. 2016;48(1):304-311.   Published online 2015 April 9    DOI: https://doi.org/10.4143/crt.2014.339

Excel Download

Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
Hyerim Ha, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Dong-Wan Kim, Chul Woo Kim, Dae Seog Heo
Cancer Research and Treatment. 2016;48(1):304-311   Crossref logo
Link1 Link2 Link3
High-dose chemotherapy and autologous stem-cell transplantation for DLBCL in the rituximab era
Michael Pfreundschuh
The Lancet Oncology. 2017;18(8):989-991   Crossref logo
Link1 Link2
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma
Kensuke Kayamori, Katsuhiro Shono, Masahiro Onoda, Akira Yokota
Hematology. 2018;24(1):52-59   Crossref logo
Link1 Link2
Rituximab added to CHOP worth it among elderly patients with DLBCL
PharmacoEconomics & Outcomes News. 2005;480(1):6-6   Crossref logo
Link1 Link2 Link3
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
Pier Luigi Zinzani, Cinzia Pellegrini, Enrico Derenzini, Lisa Argnani, Stefano Pileri
Hematological Oncology. 2013;31(4):223-224   Crossref logo
Link1 Link2
Erratum: Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma
Cancer. 2011;118(13):3446-3446   Crossref logo
Link1 Link2
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma
Alberto Febbri, Alessandro Gozzetti, Luigi Rigacci
Cancer. 2011;117(15):3530-3530   Crossref logo
Link1 Link2
Effectiveness of dose reduced THP-COP like therapy with the addition of etoposide for elderly DLBCL patients
Yuko Tanaka, Seiichiro Yoshizawa, Yu Saito, Seiichiro Katagiri, Daigo Akahane, Hiroaki Fujimoto, Tetsuzo Tauchi, Yoshikazu Ito, Kazuma Ohyashiki
Annals of Oncology. 2017;28:ix111   Crossref logo
Link1 Link2 Link3
Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma
Antonino Musolino, Daniela Boggiani, Michele Panebianco
Cancer. 2011;117(15):3531-3531   Crossref logo
Link1 Link2
Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
Nalan Akyurek, Aysegul Uner, Mustafa Benekli, Ibrahim Barista
Cancer. 2011;118(17):4173-4183   Crossref logo
Link1 Link2
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.